

Novartis India Limited

Regd. off: Sandoz House, Shivsagar Estate, Dr Annie Besant Road, Worli, Mumbai 400 018.

PART I STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2013 In ₹ million

Sr. No	Particulars	3 months ended	3 months ended	3 months ended	9 months ended	9 months ended	Year ended
		31.12.2013	30.9.2013	31.12.2012	31.12.2013	31.12.2012	31.3.2013
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Income from Operations						
	(a) Net Sales/Income from Operations (Net of Excise Duty)	2,185.4	2,091.8	2,284.5	6,467.5	6,781.5	8,861.0
	(b) Other Operating Income	61.0	47.4	53.5	149.1	126.2	172.6
	Total Income from Operations (Net)	2,246.4	2,139.2	2,338.0	6,616.6	6,907.7	9,033.6
2.	Expenses						
	(a) Cost of Materials Consumed	107.9	85.0	96.6	314.0	276.4	403.6
	(b) Purchases of Stock-in-Trade	901.5	937.5	855.9	2,641.4	2,666.2	3,579.3
	(c) Changes in Inventories of Finished Goods and Stock-in-Trade	57.1	18.4	9.1	157.3	(102.6)	(266.4)
	(d) Employee Benefits Expense	406.6	412.8	423.0	1,278.4	1,201.6	1,623.0
	(e) Depreciation and Amortisation Expense	9.4	9.3	10.6	28.0	25.8	35.9
	(f) Other Expenses	779.4	792.1	719.9	2,311.5	2,050.9	2,793.7
	Total Expenses	2,261.9	2,255.1	2,115.1	6,730.6	6,118.3	8,169.1
3.	(Loss)/Profit from Operations before Other Income and Finance Costs	(15.5)	(115.9)	222.9	(114.0)	789.4	864.5
4.	Other Income	231.8	255.1	198.5	692.4	613.0	831.9
5.	Profit from Ordinary Activities before Finance Costs	216.3	139.2	421.4	578.4	1,402.4	1,696.4
6.	Finance Costs	0.7	0.6	4.6	2.0	5.8	2.2
7.	Profit from Ordinary Activities before Tax	215.6	138.6	416.8	576.4	1,396.6	1,694.2
8.	Tax (Credit)/Expense (Net) (including Deferred Tax)	63.3	(316.9)	126.8	(170.1)	443.4	496.9
9.	Net Profit for the period	152.3	455.5	290.0	746.5	953.2	1,197.3
10.	Paid-up Equity Share Capital (Face Value ₹ 5 each)	159.8	159.8	159.8	159.8	159.8	159.8
11.	Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)						8,842.3
12.	Earnings Per Share - (of ₹ 5 each) (not annualised) Basic and Diluted (₹)	4.77	14.25	9.07	23.36	29.82	37.46

PART II SELECT INFORMATION FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2013

	Particulars	3 months ended	3 months ended	3 months ended	9 months ended	9 months ended	Year ended
		31.12.2013	30.9.2013	31.12.2012	31.12.2013	31.12.2012	31.3.2013
A	PARTICULARS OF SHAREHOLDING						
1.	Public Shareholding						
	- Number of Shares	7,990,200	7,990,200	7,535,995	7,990,200	7,535,995	7,535,995
	- Percentage of Shareholding	25.00	25.00	23.58	25.00	23.58	23.58
2.	Promoter and Promoter Group Shareholding						
	(a) Pledged / Encumbered						
	- Number of Shares	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total Share Capital of the company)	-	-	-	-	-	-
	(b) Non-Encumbered						
	- Number of Shares	23,970,597	23,970,597	24,424,802	23,970,597	24,424,802	24,424,802
	- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total Share Capital of the company)	75.00	75.00	76.42	75.00	76.42	76.42

Particulars	3 months ended
	31.12.2013
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	1
Disposed of during the quarter	1
Remaining unsolved at the end of the quarter	-

SEGMENT REVENUE, RESULTS AND CAPITAL EMPLOYED

In ₹ million

Sr. No	Particulars	3 months ended	3 months ended	3 months ended	9 months ended	9 months ended	Year ended
		31.12.2013	30.9.2013	31.12.2012	31.12.2013	31.12.2012	31.3.2013
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Segment Revenue						
	(a) Pharmaceuticals	1,429.1	1,372.1	1,618.2	4,429.0	4,923.5	6,348.5
	(b) Generics	159.9	140.9	157.1	450.0	462.8	625.2
	(c) OTC	376.8	335.3	323.0	910.6	805.4	1,104.6
	(d) Animal Health	280.6	290.9	239.7	827.0	716.0	955.3
	Total Income from Operations (Net)	2,246.4	2,139.2	2,338.0	6,616.6	6,907.7	9,033.6
2.	Segment Results						
	(a) Pharmaceuticals	(29.0)	(116.8)	155.8	(53.1)	686.2	737.8
	(b) Generics	(1.7)	25.7	76.8	60.4	175.1	220.8
	(c) OTC	51.4	53.7	57.8	81.9	107.0	162.5
	(d) Animal Health	24.0	9.0	6.1	31.5	26.6	40.2
	Total	44.7	(28.4)	296.5	120.7	994.9	1,161.3
	Add/(Less):						
	(a) Finance Costs	(0.7)	(0.6)	(4.6)	(2.0)	(5.8)	(2.2)
	(b) Other Unallocable Expenditure	(59.6)	(83.1)	(72.9)	(220.1)	(201.5)	(290.9)
	(c) Other Unallocable Income	231.2	250.7	197.8	677.8	609.0	826.0
	Profit from Ordinary Activities before tax	215.6	138.6	416.8	576.4	1,396.6	1,694.2
3.	Capital Employed (Segment Assets less Segment Liabilities)						
	(a) Pharmaceuticals	98.4	252.0	238.1	98.4	238.1	258.7
	(b) Generics	61.6	106.1	62.3	61.6	62.3	103.5
	(c) OTC	(85.3)	5.7	(18.7)	(85.3)	(18.7)	(53.8)
	(d) Animal Health	326.5	331.8	291.8	326.5	291.8	326.5
	Total	401.2	695.6	573.5	401.2	573.5	634.9
	Add: Unallocable Corporate Assets less Unallocable Corporate Liabilities	9,347.4	8,900.7	8,558.4	9,347.4	8,558.4	8,367.2
	Total Capital Employed	9,748.6	9,596.3	9,131.9	9,748.6	9,131.9	9,002.1

Notes:

- The above results were reviewed by the Audit Committee at its meeting held on 23rd January 2014 and approved at the meeting of the Board of Directors held on that date.
- On 30th May, 2013, Novartis AG reduced its promoter shareholding in the company to 75% enabling the company to comply with the minimum 25% public shareholding requirements as set out in Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended.
- Tax Credit for the nine months ended 31st December 2013 includes write back of provision for current tax for the Assessment Year 1995-1996 amounting to Rs 366.9 million (net of additional current tax charge for the Assessment Years 1992-1993 to 1994-1995 amounting to Rs 20.8 million on account of various matters). The aforesaid write back is on account of a favourable Order of the Income Tax Appellate Tribunal, received during the quarter ended 30th September 2013, for non-taxability of consideration from sale of an undertaking.
- The results for the quarter ended 31st December 2013 have been subjected to limited review by the statutory auditors of the company.
- Figures for the prior periods have been regrouped where necessary.

By Order of the Board

Ranjit Shahani
Vice Chairman and Managing Director
Mumbai, 23rd January 2014